These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30999559)

  • 61. Counterfeit anti-infective drugs.
    Newton PN; Green MD; Fernández FM; Day NP; White NJ
    Lancet Infect Dis; 2006 Sep; 6(9):602-13. PubMed ID: 16931411
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [TBL] [Abstract][Full Text] [Related]  

  • 63. From medical tradition to traditional medicine: A Tibetan formula in the European framework.
    Schwabl H; Vennos C
    J Ethnopharmacol; 2015 Jun; 167():108-14. PubMed ID: 25446636
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bacteriophage therapy: a regulatory perspective.
    Pelfrene E; Willebrand E; Cavaleiro Sanches A; Sebris Z; Cavaleri M
    J Antimicrob Chemother; 2016 Aug; 71(8):2071-4. PubMed ID: 27068400
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Biosimilars and regulatory authorities.
    Minghetti P; Rocco P; Del Vecchio L; Locatelli F
    Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.
    Verbeken G; Pirnay JP; De Vos D; Jennes S; Zizi M; Lavigne R; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):161-72. PubMed ID: 22527355
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Criteria for Selecting Suitable Infectious Diseases for Phage Therapy.
    Harper DR
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29621149
    [TBL] [Abstract][Full Text] [Related]  

  • 68. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 69. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Safety monitoring of cell-based medicinal products (CBMPs)].
    Funk MB; Frech M; Spranger R; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
    Robinson S; Delongeas JL; Donald E; Dreher D; Festag M; Kervyn S; Lampo A; Nahas K; Nogues V; Ockert D; Quinn K; Old S; Pickersgill N; Somers K; Stark C; Stei P; Waterson L; Chapman K
    Regul Toxicol Pharmacol; 2008 Apr; 50(3):345-52. PubMed ID: 18295384
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Medicinal Product Regulation: Portugal׳s Framework.
    Herdeiro MT; Bastos PD; Teixeira-Rodrigues A; Roque F
    Clin Ther; 2016 Sep; 38(9):2118-2126.e2. PubMed ID: 27574988
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Early Preclinical Development Program for Locally Administered Investigational Medicinal Products in Ophthalmology: Preclinical Data Required for Starting a First-in-Human Clinical Trial in Europe-Basic Considerations and 2 Case Studies.
    Toggenburger A; Trönnberg R; Galland A; Mathis GA
    Ther Innov Regul Sci; 2018 May; 52(3):321-328. PubMed ID: 29714531
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Australia's National Medicines Policy is outdated and in need of review.
    Shaw B; Chisholm O
    Med J Aust; 2019 Sep; 211(6):252-254.e1. PubMed ID: 31327165
    [No Abstract]   [Full Text] [Related]  

  • 79. Evaluation of similar biotherapeutic products (SBPs): scientific principles and their implementation.
    Knezevic I
    Biologicals; 2011 Sep; 39(5):256-61. PubMed ID: 21907589
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences.
    Chanishvili N
    Curr Drug Deliv; 2016; 13(3):309-23. PubMed ID: 27090515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.